Pharmacotherapeutic candidates for myopia: A review - 19/12/20
pages | 17 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Signaling molecules in retinal-scleral pathways were involved in myopia formation. |
• | Dopamine receptor activity plays a critical role in myopia. |
• | Atropine showed consistent effectiveness as pharmaceutical treatment for myopia. |
• | Ongoing clinical trials to control myopia were vigorously conducted. |
Abstract |
This review provides insights into the mechanism underlying the pathogenesis of myopia and potential targets for clinical intervention. Although the etiology of myopia involves both environmental and genetic factors, recent evidence has suggested that the prevalence and severity of myopia appears to be affected more by environmental factors. Current pharmacotherapeutics are aimed at inhibiting environmentally induced changes in visual input and subsequent changes in signaling pathways during myopia pathogenesis and progression. Recent studies on animal models of myopia have revealed specific molecules potentially involved in the regulation of eye development. Among them, the dopamine receptor plays a critical role in controlling myopia. Subsequent studies have reported pharmacotherapeutic treatments to control myopia progression. In particular, atropine treatment yielded favorable outcomes and has been extensively used; however, current studies are aimed at optimizing its efficacy and confirming its safety. Furthermore, future studies are required to assess the efficacy of combinatorial use of low-dose atropine and contact lenses or orthokeratology.
Le texte complet de cet article est disponible en PDF.Abbreviations : ECM, bFGF, DFP, FGF-2, FDM, GABA, GAGs, MMPs, miRNA, LIM, NO, NOS, ortho-K, RPE, RA, RAR-β, 5-hydroxytryptamine, or 5-HT, SNPs, SLRPs, siRNA, TIMPs, TGF-β, 7-MX
Keywords : Atropine, Axial growth, Dopamine, Myopia, Pharmaceutical intervention, Sclera
Plan
Vol 133
Article 111092- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?